Clinical trials: Pulmonary Ventilation
Bronchiolitis
Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis
Prospective, Double Blind, Randomized Single-Center, Evaluation of Safety and Tolerability of Nitric Oxide Given Intermittently via Inhalation to Subjects with Bronchiolitis-Phase IIa Bronchiolitis is defined as an infection of…
- Trial name
- NCT01768884
- Testing
- Nitric Oxide
- Where
- Israel
- Volunteers
- 43 people
- Sponsor
- Beyond Air Inc.
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to…
- Trial name
- NCT00961038
- Testing
- Ciprofloxacin (PulmoSphere, BAYQ3939)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Emphysema, Pulmonary, Emphysema or COPD
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe.
- Trial name
- CONVERT_II (NCT06035120)
- Testing
- AeriSeal System
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 200 people
- Sponsor
- Pulmonx Corporation
Acute Respiratory Distress Syndrome
KL₄Surfactant Treatment in Patients With ARDS
Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS).
- Trial name
- NCT00215553
- Testing
- A.1 Lucinactant, B.3 SoC, A.2 Lucinactant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Windtree Therapeutics
Respiratory Distress Syndrome, Newborn
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
This study is to evaluate the safety and efficacy of lucinactant for inhalation in conjunction with nCPAP, in comparison to nCPAP alone, in preterm neonates with RDS, as assessed by the incidence of and time to respiratory…
- Trial name
- NCT04264156
- Testing
- Lucinactant for Inhalation, nCPAP Only
- Where
- 3 sites in Poland
- Volunteers
- 12 people
- Sponsor
- Windtree Therapeutics
COPD, ILD
Individualized Plan for Improving Adherence to Portable Oxygen Therapy in Patients With Respiratory Pathology
Pilot study with patients with prescription of portable oxygen therapy, to test the impact on adherence of a patient-centered empowerment program, with contents on the nature of the respiratory pathology, the symptom of dyspnea…
- Conditions
- COPD, ILD, Dyspnea
- Trial name
- PIMAOX (NCT04691336)
- Testing
- Educational and Training with counselling
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Air Liquide Healthcare Spain
Coughing, Throat Irritation
A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being
This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged…
- Trial name
- NCT07694284
- Testing
- Super Lungs Liquid Drops
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- SuperBonsai Inc.
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
SM04646-IPF-03 is a Phase 2a, multi-center, open-label study evaluating the safety and efficacy of a single inhaled, nebulized dose of SM04646 solution over a 12-week treatment regimen in subjects with mild to moderate IPF.
- Trial name
- NCT03591926
- Testing
- SM04646
- Where
- 6 sites in Australia, New Zealand
- Sponsor
- Biosplice Therapeutics, Inc.
COPD
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF6523 DPI in healthy male subjects first and then in COPD subjects after single or repeated dosesof CHF6523.
- Trial name
- CHF6523 (NCT04032535)
- Testing
- CHF6523
- Where
- United Kingdom
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Chronic Obstructive Lung Disease
Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients
The Breathe Ventilator is a lightweight, wearable ventilator that has received U.S. FDA clearance for use in patients with respiratory difficulty.
- Trial name
- NCT01596023
- Testing
- Breathe NIOV Ventilator
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Breathe Technologies, Inc.
Respiratory Distress Syndrome
The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
The primary objective of this study is to evaluate the safety and efficacy of lucinactant for inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32 weeks gestational age who are receiving nasal…
- Trial name
- NCT02636868
- Testing
- Lucinactant delivered via investigational delivery device, nCPAP
- Where
- 54 sites in United States, Canada and 6 more
- Volunteers
- 221 people
- Sponsor
- Windtree Therapeutics
Asthma
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting…
- Trial name
- NCT01493882
- Testing
- JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Covid19
Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis
This is a confirmatory study that seeks to examine whether respiratory-responsive vocal biomarkers have potential to respond to COVID-19 infection status and respiratory symptom severity.
- Trial name
- NCT04582331
- Testing
- Smartphone-based voice and self-reported symptom collection
- Where
- 4 sites in United States, India
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sonde Health
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
COPD, Chronic Hypercapnic Respiratory Failure
Intelligent Volume Assured Pressure Support to Improve Sleep Quality and Respiratory Events in Patients With Non Invasive Ventilation
Aim of this prospective randomized trial is to compare non invasive ventilation (NIV) with pressure control (BiPAP-ST) to volume assured pressure support (iVAPS) with regards to sleep quality and alveolar ventilation in patients…
- Trial name
- NCT01986413
- Testing
- pressure controlled ventilation BIPAP ST, volume assured pressure support IVAPS, NIV
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Asthma
Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch…
- Trial name
- QVM149 (NCT03108027)
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure (ARF)
The Association Between IL17, Acute Respiratory Distress Syndrome and Acute Respiratory Failure
This study will look at a protein called Interleukin (IL)-17A and how it relates to health markers in patients with a serious lung condition known as Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- FROG-ARDS (NCT06779942)
- Where
- 2 sites in France
- Volunteers
- 414 people
- Sponsor
- Bayer